News and Announcements
TAIM Investments funds continue to outperform despite turbulent month on global share markets
- Published September 10, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
After some testing times during the month, global share markets had steadied somewhat by the end of the month. The Australian share market had its first step backward this month with the ASX200 declining by -3.1% during August.
TAIM’s Funds did not escape the general price volatility. Despite our principal Momentum Fund receding during the month, the Fund continues to outperform its benchmark on a 3-month, 6-month, 12-month and since inception basis.
The stellar run in 2019 for our Leveraged Fund also slowed this month. Calendar Year performance continues to be very healthy, and the Fund remains an impressive +29% up on its benchmark since inception.
About TAIM Investments
TAIM Investments operates two Australian equities investment funds. Both have exhibited exceptional performance, during an initial 4-year small-scale-offering period, and now under the company’s own AFSL. Both funds have an Australian blue-chip focus – portfolio of 20 ASX200 equities, long-only, no short-selling or derivatives – and we use an automated quantitative approach to deliver superior performance.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
